OpenAI says thousands of GPT Rosalind agents found a possible cholesterol link in Perry syndrome by analyzing millions of mouse brain cells in 32 minutes
GPT-Rosalind surfaced a new lead for drug discovery: could restoring cholesterol transport protect neurons from degeneration? DCTN1 is a gene linked to Perry syndrome, a rare neurodegenerative disorder. In mouse-brain data, disrupting it increased expression of genes involved in making cholesterol. GPT-Rosalind suggested a possible explanation: cholesterol may not be reaching where neurons need it. That gives scientists a specific mechanism to test and, if confirmed, a direction for developing new treatments for neurodegenerative disorders. With @perturbai_tx and @scrippsresearch, a team of thousands of GPT-Rosalind agents worked in parallel, connecting gene-expression results from millions of mouse brain cells with scientific literature in just 32 minutes. We’re now expanding this collaboration to identify new drug targets.
Context
It is a concrete example of AI agents turning a huge biology dataset into a testable idea for a neurodegenerative disease.
GPT Rosalind is OpenAI's model for life sciences research. The work was done with PerturbAI and Scripps Research, and the result is a hypothesis to test in the lab, not a confirmed mechanism or treatment.
Deep dive
On October 21, OpenAI posted that GPT Rosalind surfaced a new lead for drug discovery: could restoring cholesterol transport protect neurons from degeneration?
It said DCTN1 is a gene linked to Perry syndrome, a rare neurodegenerative disorder. In mouse brain data, disrupting it increased the expression of genes involved in making cholesterol, and GPT Rosalind suggested cholesterol may not be reaching where neurons need it. With PerturbAI and Scripps Research, thousands of GPT Rosalind agents worked in parallel, connecting gene expression results from millions of mouse brain cells with scientific literature in 32 minutes. OpenAI said it is expanding the collaboration to find new drug targets.
OpenAI's blog says each agent investigated one gene disruption in a whole brain CRISPR atlas and searched the literature, and the reports were combined into a public reasoning atlas. The team estimated comparable human analysis would take months to a year. At the largest workload, a single agent cited 11 references while the distributed agents cited more than 700, and blinded experts preferred the distributed reports 75% of the time.
The agents also flagged a difference between the genes Tsc1 and Tsc2 in the cerebellum, relevant to tuberous sclerosis. OpenAI says experts considered the Perry syndrome hypothesis novel and worth following up, but it has not yet been tested experimentally.
What to expect next
Watch for lab experiments testing whether DCTN1 disruption changes how cholesterol is distributed in neurons, which would show whether the lead holds up. Researchers using the public reasoning atlas may report other findings. Also watch for peer reviewed publication of the method, and for OpenAI's expanded work with PerturbAI and Scripps Research to name new drug targets. Independent groups applying the same approach to other datasets will show how general it is.